PDF(Pubmed)
Abstract：
Due to their distinctive structural features, lyotropic nonlamellar liquid crystalline nanoparticles (LCNPs), such as cubosomes and hexosomes, are considered effective drug delivery systems. Cubosomes have a lipid bilayer that makes a membrane lattice with two water channels that are intertwined. Hexosomes are inverse hexagonal phases made of an infinite number of hexagonal lattices that are tightly connected with water channels. These nanostructures are often stabilized by surfactants. The structure\'s membrane has a much larger surface area than that of other lipid nanoparticles, which makes it possible to load therapeutic molecules. In addition, the composition of mesophases can be modified by pore diameters, thus influencing drug release. Much research has been conducted in recent years to improve their preparation and characterization, as well as to control drug release and improve the efficacy of loaded bioactive chemicals. This article reviews current advances in LCNP technology that permit their application, as well as design ideas for revolutionary biomedical applications. Furthermore, we have provided a summary of the application of LCNPs based on the administration routes, including the pharmacokinetic modulation property.
摘要：
由于其独特的结构特征，溶致非层状液晶纳米粒子（LCNPs），如立方体和己体，被认为是有效的药物递送系统。立方体具有脂质双层，使两个水通道交织在一起形成膜晶格。六聚体是由无数个与水通道紧密相连的六角形晶格组成的逆六角形相。这些纳米结构通常由表面活性剂稳定。该结构的膜具有比其他脂质纳米颗粒大得多的表面积，这使得装载治疗分子成为可能。此外,中间相的组成可以通过孔径来修饰，从而影响药物释放。近年来已经进行了许多研究，以改善它们的制备和表征，以及控制药物释放和提高加载的生物活性化学物质的功效。本文回顾了允许其应用的LCNP技术的最新进展，以及革命性生物医学应用的设计理念。此外，我们根据给药途径提供了LCNPs的应用摘要，包括药代动力学调制特性。
